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Selenium (Se) is an important micronutrient that, as a component of selenoproteins, inﬂu-
ences oxidative and inﬂammatory processes. Its’ levels vary considerably, with different
ethnic and geographic population groups showing varied conditions, ranging from frank
Se deﬁciencies to toxic effects. An optimum Se level is essential for the maintenance of
homeostasis, and this optimum may vary according to life stage, general state of health,
and genotype. Nutrigenetic studies of different Se levels, in the presence of genetic vari-
ants in selenoproteins, suggest that an effective dietary Se intake for one individual may
be very different from that for others. However, we are just starting to learn the sig-
niﬁcance of various genes in selenoprotein pathways, functional variants in these, and
how to combine such data from genes into pathways, alongside dietary intake or serum
levels of Se. Advances in systems biology, genetics, and genomics technologies, includ-
ing genetic/genomic, epigenetic/epigenomic, transcriptomic, proteomic, and metabolomic
information, start to make it feasible to assess a comprehensive spectrum of the biologi-
cal activity of Se. Such nutrigenomic approaches may prove very sensitive biomarkers of
optimal Se status at the individual or population level. The premature cessation of a major
human Se intervention trial has led to considerable controversy as to the value of Se sup-
plementation at the population level. New websites provide convenient links to current
information on methodologies available for nutrigenetics and nutrigenomics. These new
technologies will increasingly become an essential tool in optimizing the level of Se and
other micronutrients for optimal health, in individuals and in population groups. However,
deﬁnitive proof of such effects will require very large collaborative studies, international
agreement on study design, and innovative approaches to data analysis.
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INTRODUCTION
Selenium (Se) is an essential human micronutrient, whose sta-
tus varies signiﬁcantly across different populations and different
ethnic groups (Cook et al., 2005; Kant and Graubard, 2007; Bleys
et al., 2008; Johnson et al., 2010). Se enters the food chain through
plants, and the amount and bioavailability of Se in the soil typically
reﬂects the plant level. Se is usually provided by the diet in humans,
but may also be derived from drinking water, environmental pol-
lution, and supplementation (Robinson, 1989; Darlow et al., 1995;
Navarro-Alarcon and Cabrera-Vique, 2008; Schrauzer and Surai,
2009). It is generally considered to be low inNewZealand soils, and
is almost certainly at sub-optimal levels in a typical New Zealand
diet (Logan, 1988, 1991; Robinson, 1989; Thomson and Robinson,
1990, 1996; Levander, 1991; Dolamore et al., 1992; Darlow et al.,
1995; Dufﬁeld et al., 1999; De Jong et al., 2001; Karunasinghe et al.,
2004; Thomson, 2004a,b; Thomson et al., 2007). In contrast, the
diets of the majority of Americans (Bleys et al., 2008), and of
many but not all Europeans (Hesketh et al., 2006; Hoeﬂich et al.,
2010; Steinbrecher et al., 2010), are considered to be nutritionally
adequate for Se. While parts of China may be deﬁcient and need
innovative methods of increasing status (Yang et al., 2007; Gao
et al., 2009; Shi et al., 2010), indoor burning of coal may also lead
to Se toxicity in other Chinese populations (Guijian et al., 2007;
Xue et al., 2010).
As with other micronutrients, sub-optimal intakes of Se may
contribute to the development and severity of chronic diseases
(Zeisel, 2010). Equally, too high a level of Se is associated with tox-
icity (Reid et al., 2004; Navarro-Alarcon and Cabrera-Vique, 2008;
Gore et al., 2010; Hon et al., 2010; Rusyniak et al., 2010). The def-
inition of Se nutritional adequacy varies across populations, and
has changed with time (Levander, 1991; Thomson, 2004a; Bleys
et al., 2008; Fairweather-Tait et al., 2010). This is a more general
part of a continuous process, of re-assessing dietary requirements
and safe upper limits of micronutrients. Early deﬁnitions related
optimal Se status to the levels necessary to saturate the activity of
the glutathione peroxidase 1 (GPx-1) enzyme (Thomson, 2004a;
Ashraﬁ et al., 2007b; Lei et al., 2007; Papp et al., 2007; Steinbrenner
and Sies, 2009; Flohe et al., 2010). However, the recognition of
a wide range of selenoproteins, many of which may play a more
fundamental or equally important role in human health as com-
pared with GPx-1, has signiﬁcantly changed thinking (Castellano
et al., 2008; Allmang et al., 2009; Arbogast and Ferreiro, 2009;
Kipp et al., 2009; Lescure et al., 2009; Rayman, 2009; Arner, 2010;
Hawkes andAlkan, 2010; Zhang et al., 2010a,b). The importance is
www.frontiersin.org April 2011 | Volume 2 | Article 15 | 1
Ferguson and Karunasinghe Nutrigenetics, nutrigenomics, and selenium
FIGURE 1 | Illustration of the complexity of gene-gene interactions,
using selenium and selenoproteins as an example.This selenium pathway
can be found at http://www.wikipathways.org/index.php/Pathway:WP15, and
the ﬁgure has been redrawn from van Ommen et al. (2010a).
being recognized, not only of considering the overt health effects
of extreme micronutrient deﬁciency or excess, but also more sub-
tle effects occurring at the genetic, genomic, or epigenomic levels
(Davis and Milner, 2006; Van Ommen et al., 2008; van Ommen
et al., 2010a,b; Zeisel, 2010).
There are more than 30 genes that affect Se uptake,metabolism,
and excretion (Mithen, 2007; Allmang et al., 2009; Schomburg
and Schweizer, 2009). The complexity of selenoprotein pathways
and ways in which the genes interact with one another, is now
well documented (Castellano et al., 2008; Allmang et al., 2009;
Rayman, 2009; Schomburg and Schweizer, 2009; Figure 1). With
recent advances in genetics, genomics, and systems biology tech-
nologies, it is becoming feasible to assess the biological action of
a micronutrient in multiple metabolic pathways, including inter-
actions with other nutrients, in relation to genotype (Bermano
et al., 2007; Joost et al., 2007; Méplan et al., 2007; 2009; Cooper
et al., 2008; Williams et al., 2008; Méplan, 2011; Penney et al.,
2010; van Ommen et al., 2010b). Systems biology approaches to
determining optimal levels of micronutrients such as Se may com-
plement public health approaches (Rayman, 2008; Platz, 2010).
Two important developments may, in the future, allow us to opti-
mize Se intake to individual human requirements (Van Ommen,
2007). We are now able, at a relatively low cost, to estimate seleno-
protein genotype in relation to uptake and metabolism (Joost
et al., 2007; Méplan et al., 2007; Williams et al., 2008; Rayman,
2009). Additionally, we are able to understand the consequences
of human health status and genetic variation for expression of key
Se-related genes (Hesketh and Villette, 2002; Hesketh et al., 2006;
Hesketh, 2008). The new molecular technologies pave the way for
personalized nutrition and optimal status of micronutrients such
as Se. These approaches are embodied in the relatively new ﬁelds
of nutrigenetics and nutrigenomics. This review will consider the
implications of both of these ﬁelds for optimizing the status of Se,
and other micronutrients.
FUNCTIONS OF SELENOPROTEINS IN HUMANS
Se is present in several selenoproteins, as the amino acid selenocys-
teine (Se-Cys; Castellano et al., 2008;Allmang et al., 2009;Arbogast
and Ferreiro, 2009; Kipp et al., 2009; Lescure et al., 2009). Func-
tions of a number of the selenoproteins are now known, and
imply a role for sub-optimal Se status in a number of human
diseases including cancer and epilepsy, and sub-optimal physi-
ological functions, including thyroid and muscle function, and
spermatogenesis (Ashraﬁ et al., 2007a; Flohe, 2007; Agamy et al.,
2010; Duntas, 2010).
Approximately half of the characterized selenoproteins have
been shown to protect the cell against the action of reactive oxygen
species (ROS; Hawkes and Alkan, 2010; Higuchi et al., 2010). GPx
enzymes are necessary to regulate intracellular concentration of
hydroperoxides, and thought to play a role in antioxidant defense
mechanisms (Baliga et al., 2007; Bartel et al., 2007; Bermano et al.,
2007; Lei et al., 2007; Savaskan et al., 2007; Méplan et al., 2008).
Thioredoxin reductase (TR), together with thioredoxin, forms a
redox system with multiple roles, including redox regulation of
transcription factors and provision of reducing equivalents for the
synthesis of deoxyribonucleotides for DNA synthesis (Ferguson
et al., 2006; Papp et al., 2007). TR also carries the function of
reducing ubiquinone-10 to regenerate the antioxidant ubiquinol-
10 (Nordman et al., 2003; Xia et al., 2003; Madeja et al., 2005).
This is an important reaction in preventing peroxidation of lipids,
a complex process whereby polyunsaturated fatty acids undergo
oxidation to yield lipid hydroperoxides. During the peroxidative
pathway, several end-products are formed, includingmalondialde-
hyde, pentane, isoprostanes, and cholesterol oxides among others
(Nordman et al., 2003). Both the 15-kDa selenoprotein, Se-15 and
SePP appear to have an antioxidant function (Méplan et al., 2007,
2009; Higuchi et al., 2010; Penney et al., 2010). SePP contains
most of the Se in plasma and appears to play a key role in reg-
ulating transport of Se into other tissues (Méplan et al., 2009).
Selenophosphate synthetase 2 (SPS2) also plays a key Se donor
role (Xu et al., 2007a,b; Schoenmakers et al., 2010).
These antioxidant effects and other actions mean that one of
the key activities of many selenoproteins will be to reduce DNA
damage, either directly through interacting with free radicals, or
more indirectly, through enhanced cellular DNA repair capacity
(Baliga et al., 2007). Both these events can be measured in DNA
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from white blood cells using the single cell gel electrophoresis
(COMET) assay. At least in a canine model, Waters et al. (2003,
2005) used this approach to show a “U” shaped curve for Se
requirements to protect against DNA damage, and others have
recognized the importance of this concept (Chiang et al., 2009).
Wehave shown that an increasing serumSe level up to 100 ng/ml in
serum decreases DNA damage, and enhances the activity of DNA
repair-associated enzymes such as GPx-1 and TR (Karunasinghe
et al., 2004; Ferguson et al., 2006). However, because ourAuckland,
New Zealand population has generally low Se levels, we could not
deﬁne an optimal New Zealand level from these data.
Chronic inﬂammation has been shown to be causal in many
of the prevalent disease of the Western world, including can-
cer, heart disease, and diabetes (Sakr et al., 2007; Zhang et al.,
2010a,b). Effects on inﬂammatory response are among the other
key activities identiﬁed for selenoproteins. Selenoprotein S (Se-S)
appears to be involved in the regulation of the pro-inﬂammatory
response (Curran et al., 2005), which can be monitored by mea-
suring levels of circulating pro-inﬂammatory cytokines such as
interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis
factor-α (TNF-α). More generally, four selenoproteins, GPx-4,
SePP, selenoprotein S (SEL-S), and selenoprotein 15 (Sep-15)
have been functionally linked to the inﬂammatory processes
of 5-lipoxygenase (5-LO) metabolism, cytokine regulation, and
endoplasmic reticulum (ER) stress. Single nucleotide polymor-
phisms (SNPs) identiﬁed in these selenoprotein genes have shown
genotype-dependent modulation of inﬂammatory status and
oxidative stress (Sakr et al., 2007; Chen et al., 2009; Kipp et al.,
2009; Schomburg and Schweizer, 2009; Zhang et al., 2010a,b).
In common with other micronutrients, the physiological effect
of any given amount and/or source of Se depends on a series
of physical, chemical, and physiological processes, including the
amount ingested, the meal matrix, digestion, absorption, metab-
olism, and excretion. It does not act independently (Fairweather-
Tait et al., 2010),but acts in conjunctionwithothermicronutrients,
including zinc, folate, vitamins D, E, B2, B6, and B12, directly
or indirectly in the innate immune response, oxidative stress
response, and DNA metabolism (Erickson et al., 2000; Georgieff,
2007;Maggini et al., 2007). Each of these processes involves a com-
plex interaction among genes, gene products, and environmental
factors.
NUTRIGENETICS AND SELENIUM
Until recently, micronutrient research was conducted under the
assumption that the underlying mechanisms are the same in
all humans. A signiﬁcant effort is now being made to charac-
terize the effects of variants of key micronutrient genes within
the human population (Mathers and Hesketh, 2007; Méplan
et al., 2007; van Ommen et al., 2010b). Somewhere around
600 enzymes for which micronutrients are cofactors are known
in the human proteome, and the genetic diversity of most of
them has not been extensively characterized (Gladyshev et al.,
2004; Lobanov et al., 2009). In relation to the speciﬁc example
of Se, the current nutritional guidelines for this micronutrient
may be ideal for only a relatively small number of people. The
ﬁeld of nutrigenetics studies the effect of genetic variations on
the interaction between diet and health (Joost et al., 2007). It
recognizes the implications of genetic variability, and seeks to
optimize human diets for disease prevention, based on identiﬁ-
cation of key points of human variation and/or effects of dietary
components on the expression of key genes. Human genetic vari-
ation is projected to include about 25 million SNPs (Johnson,
2009), and an unknown, but possibly even larger, number of small
insertion/deletions (indels) plus CNVs (Erickson, 2010; Lee and
Scherer, 2010). Those SNPs that are important to gene function
include non-synonymous SNPs that may affect enzyme or protein
properties, regulatory SNPs that alter gene expression, intron splic-
ing,orRNA stability.All of these changeswill profoundly inﬂuence
the way in which the body metabolizes and utilizes nutrients such
as Se (Mathers and Hesketh, 2007; van Ommen et al., 2010b;
Zeisel, 2010).
An increasing number of Se studies have used nutrigenetic
approaches, in considering the functionality of various SNPs in
selenoproteins, and the effects of such functional SNPs on indi-
vidual Se requirements (Villette et al., 2002; Bermano et al., 2007;
Mathers and Hesketh, 2007; Méplan et al., 2007, 2008, 2010;
Cooper et al., 2008; Hesketh, 2008; Peters et al., 2008; Lietz and
Hesketh, 2009; Sutherland et al., 2010; Xiong et al., 2010). There
is also one study suggesting that CNVs may also be important
for Se metabolism and function (Amar et al., 2010). Three typical
examples, relevant to SNPs, follow:
– Leukotrienes produced from inﬂammatory cells mediate the
inﬂammatory response and their synthesis has been shown to
be 5-LO dependent (Villette et al., 2002). Fatty acid hydroper-
oxides are potential activators of 5-LO, so the reduction of these
intracellular hydroperoxides to hydroxides by GPx-4 and sub-
sequent 5-lipoxygenase (5-LO) inhibition is proposed to be a
key reaction capable of inﬂuencing the intensity and duration
of an immune response. A SNP identiﬁed as a C→T variation
located at position 718 in the 3′ untranslated region (3′UTR)
of the human GPx-4 gene has been described, and shown to
contribute to a genotype-dependent functionally signiﬁcant dif-
ference in levels of 5-LO metabolites (Villette et al., 2002). A
genotype-dependent role for GPx-4 in lipoxygenase metabo-
lism that is linked to the inﬂammatory response as a function
of 5-LO activation was proposed.
– A role for SEL-S in the translocation of misfolded proteins
from the ER to the cytosol for ubiquitin dependent protea-
somal degradation and the regulation of the production of
pro-inﬂammatory cytokines has been described (Curran et al.,
2005). These authors proposed that the accumulation of mis-
folded proteins promotes ER stress resulting in the activation
of nuclear factor kappa β (NFκβ) and transcription of pro-
inﬂammatory cytokines. The removal of misfolded proteins
is thought to prevent ER stress and the pro-inﬂammatory
response. The expression of SEL-S has been shown to be up-
regulated in response to pro-inﬂammatory cytokines, itself
down regulating pro-inﬂammatory cytokine production. Inves-
tigation of the functional inﬂuence of a SNP described as a
G→A variation located at position 105 in the SEL-S promoter
region that mediates SEL-S expression in response to pro-
inﬂammatory cytokines demonstrated that a reduction in SEL-S
expression and translocation of misfolded proteins resulted in
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the persistence of the pro-inﬂammatory response measured as
plasma levels of IL-1β, IL-6, and TNF-α (Curran et al., 2005).
– Sep-15 is thought to be involved in the quality control of
ER protein folding (Korotkov et al., 2001; Labunsky et al.,
2006; Labunskyy et al., 2007, 2009). More speciﬁcally, it has
been shown to associate with the protein folding sensor UDP–
glucose:glycoprotein glucosyltransferase (UGT) that regulates
the calnexin cycle in the ER (Labunsky et al., 2006). A role for
Sep-15 in the modulation of UGT activity or the assessment of
protein structure is proposed, and supported by the ﬁnding that
Sep-15 expression is increased in response to the accumulation
of unfoldedproteins in the ER (Labunsky et al., 2006). TwoSNPs
located in the SECIS portion of the 3′UTR of Sep-15 have been
identiﬁed that inﬂuence Sep-15 translation and responsiveness
to selenium intake (Hu et al., 2001; Kumaraswamy et al., 2002;
Penney et al., 2010; Sutherland et al., 2010).
The above examples are just a small proportion of those avail-
able studies associating variant SNPs in genes for selenoproteins,
in conjunction with low Se status, with increased susceptibility to
various disease or physiological conditions. Until now, most of
these studies have considered a single micronutrient (Se) and one
or several variants in a gene or pathway at a time. However, many
of these early studies had small study numbers, and not greatly sig-
niﬁcant p values. For example, Villette et al. (2002), studied only
66 individuals, among which differences signiﬁcant at p< 0.002
were found. This contrasts unfavorably with the numbers of sub-
jects now being utilized to prove single gene associations with
disease. For example, a recent meta-analysis increased the number
of conﬁrmed Crohn’s disease susceptibility loci to 71 (Franke et al.,
2010). This publication utilized a meta-analysis of six genome-
wide association studies (GWAS), comprising 6,333 affected cases
and 15,056 controls. Conﬁrmationwas provided by studying a fur-
ther 15,694 cases, 14,026 controls, and 414 parent–offspring trios,
with p< 1× 10−7 providing a cut off point for statistical signiﬁ-
cance. If these sorts of numbers are now considered essential for
single gene associations with disease, how do we even envisage the
increased orders of magnitude of numbers thatwould be necessary
to deﬁnitively prove gene–gene or gene–diet interactions?
There is increasing recognition of the complexity and interac-
tions among genes, gene pathways, and multiple micronutrients
(Pico et al., 2008; Schomburg and Schweizer, 2009; van Ommen
et al., 2010b). An open source description of gene pathways for
various micronutrients, including Se, is publically available at
http://micronutrients.wikipathways.org. (Pico et al., 2008). This
offers a search option for pathways, genes and metabolites, a
pathway editor, different download options, and web services for
programmatic access. A systems biology approach has been sug-
gested as necessary to integrate anddata frommultiple systems and
technologies (Hesketh, 2008; Allmang et al., 2009; Schomburg and
Schweizer, 2009). New methods are becoming available for com-
bining the interaction of effects of genotype with dietary factors
alongside measurements of factors that inﬂuence transcript levels
of multiple genes (Parts et al., 2011). While such novel analytical
methods have been applied to factors that affect gene expression
in a yeast dataset, they await application to human studies at
this time.
NUTRIGENOMICS AND SELENIUM
In the past, direct measurement of plasma micronutrients or bio-
markers have been used to quantify micronutrient status. Nutrige-
nomics is the study of the response of humans to food and
food components using genomics, proteomics, and metabolomics
approaches (Daniel et al., 2008;Hesketh,2008;Kaput,2008). These
approaches potentially provide powerful new tools to assess the
impact of Se status on the health of an individual.
GENE EXPRESSION
Patterns and endpoints of gene expression are analyzed through
transcriptomics and proteomics. Such analyses enabling an under-
standing of the mechanisms of action of Se are increasing
(Bartel et al., 2007;Chun et al., 2007;Kibriya et al., 2007;Novoselov
et al., 2007; Zeng and Botnen, 2007; Hesketh, 2008; Pagman-
tidis et al., 2008; Carlson et al., 2009; Yuzbasioglu et al., 2009;
Bartel et al., 2010). To integrate these datasets, pathways that
graphically show gene expression changes in association with Se
levels are being developed (van Ommen et al., 2010a,b). Cur-
rently, gene expression is incorporated by including enzymes and
transcription levels (Joost et al., 2007; Van Ommen et al., 2008).
However, this is changing, with new analytical methods appearing
(e.g., Parts et al., 2011).
An example of the potential of the approaches to deﬁne the
relative roles of genetic variations and Se intake in a human
population is provided by Méplan et al. (2009). They studied
SePP, the major plasma selenoprotein, with both transport and
antioxidant functions, which exists in human plasma as two iso-
forms, of approximately 50 and 60 kDa. They considered the
effect of SNPs in the SEPP-1 gene, on the proportions of SePP
plasma isoforms in relation to Se supplementation, and disease
status. SePP was isolated from the plasma of healthy volun-
teers, and from colon cancer patients and controls, before and
after a 6-week supplementation with 100μg sodium selenite. The
distribution of SePP isoforms was analyzed by Western blot-
ting. In healthy volunteers, the relative abundance of each iso-
form primarily depended on two SNPs in the SEPP1 gene, but
only in the absence of Se supplementation. These are the two
functional SNPs, rs3877899, predicted to cause an Ala-to-Thr
amino acid change at position 234, and rs7579, located in the 3′-
untranslated region of SEPP-1 mRNA. This difference between
genotypes disappeared after Se supplementation. A genotype-
dependent reduction in the proportion of the 60-kDa isoform
was also seen in patients with colorectal cancer as compared with
controls.
A useful review on the regulation of selenoprotein gene expres-
sion is provided by Schomburg and Schweizer (2009). They draw
attention to the expression of selenoproteins as almost classic text-
book examples of different levels of regulatory control on protein
biosynthesis. That is, gene expression can be regulated during
transcription, RNA processing, translation, and posttranslational
events, as well as through control of the stability of metabolic
intermediates andﬁnal products. Closely regulated expressionpat-
terns of selenoproteins are present in different tissues, and show
differences between male and female individuals. They are often
modiﬁed during disease or disease processes, including cancer,
inﬂammation, or neurodegeneration.
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PROTEOMICS
Méplan (2011) uses Se as an example of a trace element that can
inﬂuence aging, and how these effects can be studied through
transcriptomics and proteomics technologies. Such approaches in
animal models have enabled identiﬁcation of downstream tar-
gets of Se in pathways related to age-related diseases. However,
future approaches that combine nutrigenomics with longevity
studies in humans will be necessary to identify comparable targets
in humans.
Traditional Se indexes, such as Se serum or plasma concentra-
tions, do not explain population differences or chemoprotective
effects. Mahn et al. (2009) suggested that knowledge of a group
of proteins that respond to Se supplementation could be useful
in assessing its’ metabolic status in an individual. They used a
rat model to consider the effects of dietary supplementation with
sodium-selenate on the plasma proteome. Groups of six rats were
fed a basic diet supplemented with sodium-selenate at 1.9μg of
Se per gram of food, in comparison with a group on a low Se diet,
for 10 weeks. The authors showed signiﬁcant changes of the levels
of ﬁbrinogen, apolipoproteins, haptoglobin, and transthyretin in
the high Se group. They suggest that, more generally, changes in
the proteomic proﬁle due to Se supplementation could be used in
human studies to assess the metabolic status of Se.
METABOLOMICS
This ﬁeld deﬁnes the metabolic network(s) linked to gene expres-
sion. Powerful new metabolomics approaches, coupled with a
number of useful web-based tools, permit a comprehensive analy-
sis of metabolites in the context of an integrated evaluation
of biological activity (Xia et al., 2008; Forsythe and Wishart,
2009; Wishart, 2009; Wishart et al., 2009; Xia and Wishart,
2010a,b). In these pathways, intracellular mechanisms related
to micronutrient activity are linked to plasma and blood cell
membrane concentrations of all relevant metabolites, including
proteins (Wishart, 2007; Berjanskii et al., 2009; Xia et al., 2009;
Xia and Wishart, 2010a,b).
These approaches were used by Fan et al. (2006) to map the
metabolites induced by two different forms of Se, selenite, and
selenomethionine, in animal models and human studies.
EPIGENETICS
This has been deﬁned as effects on gene expression in the absence
of heritable DNA changes. It is likely that changes in selenoprotein
expression result not only from changes in DNA, but also from
epigenetic effects (Davis and Milner, 2006; Baliga et al., 2007; Hes-
keth, 2008). These changes may relate to effects on transcription
factor,microRNAs, andDNAmethylation (Ferguson, 2009).How-
ever, epigenetic effects of Se have not been extensively described
to date, at least in humans.
THE USE OF NUTRIGENETIC AND/OR NUTRIGENOMICS
APPROACHES TO PROVIDE INSIGHT INTO THE POTENTIAL
VALUE OR HAZARDS OF SE SUPPLEMENTATION
A considerable literature has linked deﬁciency of Se to elevated
risk of cancer, especially prostate cancer (Clark et al., 1993; Combs
et al., 1997; Clark and Jacobs, 1998; Nelson et al., 1999; Dufﬁeld-
Lillico et al., 2002, 2003a; Karunasinghe et al., 2004). In the Nutri-
tional Prevention of Cancer (NPC) study, supplementation with
Se as Se-yeast was shown to reduce the risk of prostate cancer in
subjects with low Se nutritional status (Clark et al., 1996, 1998;
Dufﬁeld-Lillico et al., 2003a,b).
Recently, considerable concerns about possible adverse effects
of Se supplementation have been raised by the premature cessa-
tion of the SELECT (the Selenium and Vitamin E Cancer Pre-
vention Trial), the largest-ever prostate cancer prevention trial
(Hoque et al., 2001; Klein et al., 2001, 2003; Cook et al., 2005;
Lippman et al., 2005; Dunn et al., 2009). The rationale for this
study was based partly upon early results from the NPC study.
Exhaustive attempts were made to recruit large numbers of Amer-
ican men, including ethnic minorities (Cook et al., 2005; Lipp-
man et al., 2005), involving extensive publicity and considerable
expense (Thompson et al., 2005). However, the trial was contro-
versially stopped partway through its’ planned course, because
of safety concerns (Lippman et al., 2009; Mueller et al., 2009;
Schrauzer, 2009).
Even in the NPC study, not all individuals appeared to ben-
eﬁt from Se supplementation (Dufﬁeld-Lillico et al., 2003a,b).
For example, there is evidence that a high level of serum Se
was associated with a slightly elevated risk of aggressive prostate
cancer. However, the increased risk only occurred in individ-
uals carrying a certain variant form of the superoxide dismu-
tase (SOD2) gene (Li et al., 2005). In vitro studies have sug-
gested that protection against DNA damage by various Se analogs
occurs through the tumor suppressor p53 gene, and would not
occur in the presence of the variant enzymes (Zhao et al., 2006;
Sarveswaran et al., 2010). Tsavachidou et al. (2009) completed
a randomized, placebo-controlled phase IIA study of prostate
cancer patients before prostatectomy, and considered effects of
selenomethionine on gene expression proﬁles. They showed that
whether events appeared beneﬁcial or detrimental was related to
p53 status.
We have previously suggested that Se requirements should be
based on a combination of genotype, and biomarkers that predict
cancer risk (Karunasinghe et al., 2004; Ferguson et al., 2006). There
is no current agreement as to how to deﬁne all relevant genetic
variants, and how to combine and integrate data for gene–gene
and gene–environment interactions, although it is clear that they
are very important (van Ommen et al., 2010b). We have shown
the application of metabolomic biomarkers to the modulation
of inﬂammation in animal models (Lin et al., 2010), and these
approaches are potentially applicable to optimizing the intake of
Se in human populations.
DATABASES RELEVANT TO NUTRIGENETIC AND
NUTRIGENOMIC STUDIES ON SE
The nutritional phenotype database (dbNP) is an infrastructural
activity which allows storage, processing, and meaningful queries
of information on micronutrient-oriented human and animal
model intervention studies with all omics components included
(genetics, transcriptomics, proteomics, metabolomics, biomark-
ers), together with a detailed description of the study design
(van Ommen et al., 2010a,b). dbNP also allows additional analy-
ses of existing samples from nutritional intervention studies, and
encourages the future collection and analysis of samples for this
purpose.
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A number of databases, such as the Gene Ontology database1,
collect relevant information for genes and gene variants. Tradi-
tionally the most relevant resource for the relation between genes
and (disease) phenotype is the OMIM database (van Ommen
et al., 2010a). The Human Variome Project2 has also begun to
develop standards for identifying, characterizing, and databasing
gene variations, and their association with clinical or other pheno-
types (Kohonen-Corish et al., 2010). The micronutrient genomics
database is also important3 (van Ommen et al., 2010b), while a
number of metabolomics databases are also available (Xia et al.,
2008, 2009; Wishart et al., 2009; Xia and Wishart, 2010a,b).
CONCLUSION
Nutrigenomics and nutrigenetic studies have the power to gen-
erate large data sets, but this may be both a strength and a
weakness. A review of published human intervention studies in
nutrigenomics highlights a number of ﬂaws and inconsistencies
in current data interpretation, sizable knowledge gaps, and a need
for improved and agreed study designs that are used consistently
on an international basis (Wittwer et al., 2011). The combination
of different genomics technologies to the same sample allows cel-
lular and physiological changes to be robustly assessed throughout
all molecular layers of change. Current developments mean that
we are moving toward getting very solid data at the level of the
individual or small group of individuals. But, given the variabil-
ity between and among individuals, how do we then address the
issue of power, so that we can be certain that we can reproduce
1www.geneontology.org
2http://www.humanvariome.org
3www.micronutrientgenomics.org
and interpret gene–gene and gene–diet interactions, and recognize
their implications?
While there is great deal of interest and promise in the ﬁeld,
the published human studies of nutrigenetics, nutrigenomics, and
selenium to date may be largely considered as “proof-of-concept.”
They have demonstrated that selenium at different levels, whether
eaten in the normal diet or taken as a supplement, profoundly
affects gene expression, proteomics, and metabolic proﬁle. But it
is important not to underestimate the challenges remaining in
evaluation, interpretation, and integration of results derived from
different platforms. There is a strong argument formore concerted
actions, larger collaborative study cohorts, and cohesive and col-
legial research efforts with expert from different disciplines across
different countries.
Nutrigenetics and nutrigenomics are comparatively new tools
withwhich to studymicronutrients such as Se.A critical evaluation
of available data, incorporating omics technologies, strongly sug-
gests that the intake or dietary supplementation with micronutri-
ents such as Se shouldbeoptimized at an individual level.However,
compared with the study numbers we now require before con-
cluding statistical signiﬁcance of an individual gene in relation to
disease susceptibility, sample sizes reporting gene–diet interactions
for Se thus far have been too small to permit deﬁnitive conclusions.
A previous review in this journal has pointed to the challenges
in this ﬁeld (Zeisel, 2010). Despite the challenges, we suggest
that nutrigenetic and nutrigenomic technologies will increasingly
become essential tools to study the physiological effects and opti-
mal dietary intake of this important micronutrient in the future.
However, international collaborations, agreed study design and
analytical methods, alongside new generation genomics technolo-
gies will be essential to take the ﬁeld to the next plateau and begin
to release its real potential.
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